BioNeutra Global Overview
Latest ROE for BioNeutra Global: 7.41% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow7.41%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for BGACF is 7.41%. That is below the sector sector average of 11.73%. Investors often review this figure alongside BioNeutra Global's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, BGACF currently prints 7.41% for ROE, while the sector average sits near 11.73%. That is roughly 36.8% below the sector mean. Large gaps often invite a closer look at BioNeutra Global's growth, margins, and balance sheet.
Return on Equity shows how effectively BioNeutra Global converts resources into returns. At 7.41%, BGACF may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting BGACF's ROE (7.41%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
